ABSTRACT
Cancer treatment-induced thrombocytopenia (CTIT) is a common adverse event during anti-tumor treatment, of which incidence is related to tumor classification, regimens, course of chemotherapy, etc. CTIT may result in a series of events including bleeding, dose intensity reduction, chemotherapy delay, and in severe cases, even the need for platelet transfusion, ultimately affecting the implementation of treatment plan, increasing the cost of treatment, reducing treatment effect and quality of life, and leading to a poor prognosis. The treatment of CTIT should first identify the cause, assess the risk of bleeding, and then adopt treatment strategies according to the cause and severity of CTIT. The main treatments of CTIT include platelet transfusion, application of various types of platelet-producing drugs, and measures to reduce the additional loss of platelets. Among them, platelet-producing drugs mainly refer to platelet-stimulating factors, including recombinant human thrombopoietin (rhTPO), recombinant human interleukin 11(rhIL-11), and thrombopoietin receptor agonists (TPO-RAs). In addition, traditional Chinese medicine also has some assistance in raising platelets. Pharmacological prophylaxis in high-risk patients may help reduce the incidence and severity of CTIT. This consensus aims to support Chinese oncologists in the diagnosis and treatment of CTIT in China, reduce the risk of bleeding and improve the quality of life of patients.
Subject(s)
Antineoplastic Agents , Neoplasms , Thrombocytopenia , Humans , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , China , Neoplasms/drug therapy , Thrombocytopenia/chemically induced , Thrombocytopenia/diagnosis , Thrombocytopenia/drug therapy , Thrombocytopenia/prevention & control , Thrombopoietin/therapeutic use , Interleukin-11/therapeutic use , Receptors, Thrombopoietin/agonistsABSTRACT
SCOPE: Sweet potato (Ipomoea batatas L.) is one of the leading crops worldwide, containing high nutritional components such as fiber and polyphenols. Root tuber of Simon 1 (SIMON), a cultivar of sweet potato, is a folk food in China with a hemostasis function but lacking experimental data support. METHODS AND RESULTS: Now the protective effect of SIMON on chemotherapy-induced thrombocytopenia (CIT), a serious complication of cancer treatment, is investigated for the first time by a CIT mouse model induced by intraperitoneal injection of carboplatin. As a result, SIMON raises the number of peripheral platelets, white blood cells, and bone marrow nucleated cells in CIT mice significantly. Besides, carboplatin-induced atrophy of the thymus, spleen, and disordered metabolism of the inflammatory immune system and glycerophospholipids are also reversed by SIMON. Phytochemical analysis of SIMON indicates 16 compounds including eight phenolic derivatives, which might be associated with its anti-CIT bioactivity. CONCLUSION: Sweet potato (SIMON) may be an efficient function food in the prevention of bleeding disorders.
Subject(s)
Antineoplastic Agents , Ipomoea batatas , Thrombocytopenia , Animals , Carboplatin/metabolism , Functional Food , Ipomoea batatas/chemistry , Ipomoea batatas/metabolism , Mice , Thrombocytopenia/chemically induced , Thrombocytopenia/drug therapy , Thrombocytopenia/prevention & controlABSTRACT
BACKGROUND: Adjuvant chemotherapy with CapeOX regimen is widely used in resected rectal cancer, which brings benefits to patients. But drug-related toxicities are severe during this process; thus, survival outcomes may potentially be affected. This study explored the efficacy of two Chinese herbal injections, Aidi injection (ADI) and Brucea javanica oil emulsion injection (BJOEI), as adjuvant drugs in CapeOX adjuvant chemotherapy on rectal cancer patients. METHODS: A total of 240 cases were enrolled in this retrospective study. 80 cases received CapeOX with ADI (the ADI group), 80 cases received CapeOX with BJOEI (the BJOEI group), and the rest 80 cases received CapeOX alone (the control group). After four cycles' chemotherapy, adverse reactions (ADRs) and quality of life (QOL) were analyzed. Then, patients received follow-up for at least one year, and the endpoint was disease-free survival (DFS). RESULTS: All patients completed at least four cycles' adjuvant chemotherapy. The incidence of leukopenia and thrombocytopenia was significantly lower in the ADI group; the incidence of nausea was significantly lower in the BJOEI group; the incidence of hand-foot syndrome was significantly lower in both the ADI group and BJOEI group. Significant difference was found in the control group regarding the Karnofsky Performance Status (KPS) scores prior and posttreatment. No difference was found among three groups regarding one-year DFS. CONCLUSION: As adjuvant drugs for rectal cancer during CapeOX chemotherapy, ADI shows advantages in decreasing leukopenia and thrombocytopenia, while BJOEI results better in remitting nausea. Both two CHIs had positive impacts on decreasing hand-foot syndrome and the maintenance of patients' QOL. It is worthy of further study and promotion for CHIs.
Subject(s)
Drugs, Chinese Herbal/pharmacology , Rectal Neoplasms/drug therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brucea javanica , Case-Control Studies , Chemotherapy, Adjuvant/adverse effects , Chemotherapy, Adjuvant/methods , China/epidemiology , Colorectal Neoplasms/drug therapy , Disease-Free Survival , Drugs, Chinese Herbal/administration & dosage , Emulsions/therapeutic use , Female , Humans , Injections/methods , Leukopenia/drug therapy , Leukopenia/prevention & control , Male , Middle Aged , Nausea/drug therapy , Nausea/prevention & control , Quality of Life , Retrospective Studies , Thrombocytopenia/drug therapy , Thrombocytopenia/prevention & control , Treatment OutcomeABSTRACT
OBJECTIVE: We conducted this study to evaluate the efficacy and safety of traditional Chinese medicine (TCM) in advanced non-small cell lung cancer (NSCLC) patients who underwent chemotherapy. DESIGN: This was a prospective, open-label, randomized controlled trial. NSCLC patients at stage IIIA, IIIB, or IV were randomly assigned to either TCM plus chemotherapy or chemotherapy alone. The comprehensive TCM treatment consisted of Kang Ai injection, herbal decoction, and Zhenqifuzheng capsules. The primary endpoint was quality of life (QOL) measured by the Functional Assessment of Cancer Therapy-Lung version 4.0. The secondary endpoints were chemotherapy completion rate, tumor response, and adverse events. All assessments were done at baseline, the third week, and the sixth week. RESULTS: Thirty-nine participants were randomly assigned to the treatment group and 36 to the control group. The QOL scores were significantly improved in the treatment group compared with those of the control group in social well-being (cycle 1, Pâ=â.048; cycle 2, Pâ=â.015), emotional well-being (cycle 1, Pâ=â.047; cycle 2, Pâ=â4.29E-05), and functional well-being (cycle 1, Pâ=â.030; cycle 2, Pâ=â.003), while the QOL scores in the above 3 domains declined in the control group (Pâ<â.05). Both groups had a decline in the physical well-being score (cycle 1, Pâ=â.042; cycle 2, Pâ=â.017) and lung cancer symptom score (cycle 1, Pâ=â.001; cycle 2, Pâ=â.001) after 2 courses of intervention. The deterioration in physical well-being and lung cancer symptoms was noticeably smaller in the treatment group (Pâ<â.05). There were significant differences between the 2 groups in social well-being, emotional well-being, functional well-being, lung cancer symptom domain, and the total score (Pâ<â.05). Patients in the treatment group had a significantly lower incidence of platelet reduction than the control group (Pâ=â.028) after 2 cycles of treatment. No significant difference in nonhematological adverse events (AEs) was observed. CONCLUSION: This study illustrated that comprehensive TCM treatment could promote the QOL of NSCLC patients, alleviate symptoms, and reduce the AEs caused by chemotherapy, verifying the synergistic and attenuating effects of TCM in NSCLC patients undergoing chemotherapy. TRIAL REGISTRATION: Chinese Clinical Trial Registry (www.chictr.org.cn): ChiCTR-TRC-13003637.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Drugs, Chinese Herbal/therapeutic use , Lung Neoplasms/drug therapy , Quality of Life , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/complications , Carcinoma, Non-Small-Cell Lung/diagnosis , Drug Synergism , Drugs, Chinese Herbal/pharmacology , Female , Humans , Incidence , Lung Neoplasms/blood , Lung Neoplasms/complications , Lung Neoplasms/diagnosis , Male , Middle Aged , Neoplasm Staging , Platelet Count , Prospective Studies , Thrombocytopenia/chemically induced , Thrombocytopenia/diagnosis , Thrombocytopenia/epidemiology , Thrombocytopenia/prevention & control , Young AdultSubject(s)
Colorectal Neoplasms , Thrombocytopenia , Antineoplastic Combined Chemotherapy Protocols , Capecitabine/therapeutic use , Chemotherapy, Adjuvant , Colorectal Neoplasms/drug therapy , Fluorouracil/therapeutic use , Humans , Oxaloacetates , Recombinant Proteins/therapeutic use , Secondary Prevention , Thrombocytopenia/chemically induced , Thrombocytopenia/drug therapy , Thrombocytopenia/prevention & control , Thrombopoietin/adverse effectsABSTRACT
Huangqi, the dried root of Radix Astragali, is an essential herb in Traditional Chinese Medicine and has been used to promote hematopoiesis for centuries. Astragalus polysaccharide (ASPS), the bioactive compound of Huangqi, serves a crucial role in hematopoiesis. The aim of the present study was to investigate the hematopoietic effects, in particular the thrombopoietic effects, and the molecular mechanisms of ASPS using an irradiationinduced myelosuppressive mouse model. Colonyforming unit assays, flow cytometric analysis of apoptosis, ELISAs, Giemsa staining and western blotting were performed to determine the hematopoietic and antiapoptotic effects of ASPS. The results demonstrated that ASPS enhanced the recovery of red blood cells at day 21 following treatment, as well as platelets and white blood cells at day 14. In addition, ASPS promoted colony formation in all lineages (megakaryocytes, granulocyte monocytes, erythroid cells and fibroblasts). The morphological study of the bone marrow demonstrated that trilineage hematopoiesis was preserved in the ASPS and thrombopoietin (TPO)treated groups compared with the control group. The overall cellularity (mean total cell count/area) of the ASPStreated group was similar to that of the TPOtreated group. Additionally, in vitro experiments indicated that treatment with 100 µg/ml ASPS exhibited the maximum effect on colony formation. ASPS attenuated cell apoptosis in megakaryocytic cells via inhibiting the mitochondrial caspase3 signaling pathway. In conclusion, ASPS promoted hematopoiesis in irradiated myelosuppressive mice possibly via enhancing hematopoietic stem/progenitor cell proliferation and inhibiting megakaryocytes apoptosis.
Subject(s)
Drugs, Chinese Herbal/chemistry , Megakaryocytes/cytology , Polysaccharides/administration & dosage , Radiation Injuries, Experimental/drug therapy , Thrombocytopenia/prevention & control , Animals , Apoptosis/drug effects , Astragalus propinquus , Disease Models, Animal , Dose-Response Relationship, Drug , Hematopoiesis/drug effects , Hematopoiesis/radiation effects , Injections, Intraperitoneal , Male , Megakaryocytes/drug effects , Megakaryocytes/radiation effects , Mice , Polysaccharides/pharmacology , Radiation Injuries, Experimental/complications , Radiation Injuries, Experimental/metabolism , Thrombocytopenia/etiologyABSTRACT
PURPOSE: The use of an argatroban-based percutaneous ventricular assist device (pVAD) purge solution in a patient with suspected heparin-induced thrombocytopenia (HIT) is described. SUMMARY: A 70-year-old woman in cardiogenic shock was admitted to a coronary care unit after being discovered unresponsive at home. A transthoracic echocardiogram revealed a low ejection fraction and findings consistent with takotsubo cardiomyopathy. Administration of multiple inotropes and vasopressors was initially required for hemodynamic support. The patient was implanted with an Impella pVAD (Abiomed, Inc., Danvers, MA) using a heparin-based purge solution; an i.v. heparin infusion was initiated for supplemental systemic anticoagulation. Over the next 24 hours, the patient's platelet count decreased from 168,000 to 37,000 cells/µL. Given a differential diagnosis that included HIT, the patient was transitioned to an argatroban-based purge solution. Due to prolonged activated partial thromboplastin times, a systemic argatroban infusion was not initiated, and the patient remained fully anticoagulated throughout pVAD support with only the argatroban-based purge solution. An HIT antibody test was negative. On hospitalization day 9 (day 6 of pVAD support with argatroban use), the patient became hemodynamically stable and was weaned off pVAD support. Three days later, the platelet count had recovered to 117,000 cells/µL (from a nadir of 21,000 cells/µL). During pVAD support, the patient developed hemolytic anemia with minimal bleeding complications. CONCLUSION: Argatroban was used as a purge solution anticoagulant in a patient with an Impella pVAD and found to be a safe and effective alternative to heparin.
Subject(s)
Anticoagulants/administration & dosage , Blood Coagulation/drug effects , Heart-Assist Devices/adverse effects , Pipecolic Acids/administration & dosage , Thrombocytopenia/prevention & control , Aged , Anticoagulants/adverse effects , Arginine/analogs & derivatives , Drug Substitution , Female , Heparin/adverse effects , Humans , Shock, Cardiogenic/etiology , Shock, Cardiogenic/surgery , Sulfonamides , Takotsubo Cardiomyopathy/complications , Thrombocytopenia/chemically induced , Treatment OutcomeABSTRACT
BACKGROUND/AIMS: It has been shown, both experimentally and clinically, that water-pipe smoke (WPS) exposure adversely affects the cardiovascular system (CVS) through the generation of oxidative stress and inflammation. Betaine, a naturally occurring compound in common foods, has antioxidant and anti-inflammatory actions. However, its potential to mitigate the adverse effect of WPS on the CVS has never been reported before. This is the subject of this study in mice. METHODS: Mice were exposed daily for 30 min to either normal air (control), or to WPS for two consecutive weeks. Betaine was administered daily by gavage at a dose of 10mg/kg, 1h before either air or WPS exposure. RESULTS: Betaine mitigated the in vivo prothrombotic effect of WPS in pial arterioles and venules. Moreover, it reversed the WPS-induced decrease in circulating platelets. Likewise, betaine alleviated platelet aggregation in vitro, and the shortening of activated partial thromboplastin time and prothrombin time induced by WPS. Betaine reduced the increase of plasminogen activator inhibitor-1 and fibrinogen concentrations in plasma induced by WPS. Betaine also diminished the WPS-induced increase of plasma concentrations of interleukin 6 and tumor necrosis factor α, and attenuated the increase of lipid peroxidation and superoxide dismutase. Immunohistochemical analysis of the heart revealed an increase in the expression of inducible nitric oxide synthase and cytochrome C by cardiomyocytes of the WPS-exposed mice. These effects were averted by betaine. CONCLUSION: Our findings suggest that betaine treatment significantly mitigated WPS-induced hypercoagulability, and inflammation, as well as systemic and cardiac oxidative stress.
Subject(s)
Antioxidants/pharmacology , Betaine/pharmacology , Smoking/adverse effects , Thrombocytopenia/prevention & control , Thrombosis/prevention & control , Administration, Oral , Animals , Blood Platelets/cytology , Blood Platelets/drug effects , Blood Platelets/metabolism , Cytochromes c/genetics , Cytochromes c/metabolism , Fibrinogen/genetics , Fibrinogen/metabolism , Gene Expression/drug effects , Interleukin-6/genetics , Interleukin-6/metabolism , Lipid Peroxidation/drug effects , Mice , Mice, Inbred C57BL , Myocytes, Cardiac/cytology , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Oxidative Stress/drug effects , Partial Thromboplastin Time , Plasminogen Activator Inhibitor 1/genetics , Plasminogen Activator Inhibitor 1/metabolism , Platelet Aggregation/drug effects , Primary Cell Culture , Prothrombin Time , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolism , Thrombocytopenia/etiology , Thrombocytopenia/metabolism , Thrombocytopenia/pathology , Thrombosis/etiology , Thrombosis/metabolism , Thrombosis/pathology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Several different strategies have been adopted in attempt to recover from chemotherapy-damaged spermatogenesis that is often seen in oncologic patients. In this study, we have evaluated the impact of short period of exposure to busulphan on the haemogram and seminiferous epithelium of adult rats, focusing on spermatogonial depletion and Sertoli cell (SC) integrity. We then examined whether vitamin B12 supplementation improves the haematological parameters and spermatogonia number. The animals received 10 mg/kg of busulphan (BuG) or busulfan+vitamin B12 (Bu/B12 G) on the first and fourth days of treatment. In H.E.-stained testicular sections, the areas of the seminiferous tubule (ST) and seminiferous epithelium were measured. The number of spermatogonia in H.E-stained and PCNA-immunolabelled testicular sections was quantified. The frequency of tubules with abnormal SC nuclei or TUNEL-positive SC was evaluated. Vimentin immunofluorescence in ST was also evaluated. In BuG and Bu/B12 G, the animals showed leukopenia and thrombocytopenia, but the body weight reduced only in BuG. The areas of ST and seminiferous epithelium decreased in Bu/B12 G and BuG. In BuG, the number of H.E.-stained and PCNA-immunolabelled spermatogonia reduced significantly. The frequency of tubules containing abnormal SC nuclei and TUNEL-positive SC increased and the vimentin immunoexpression pattern changed. In Bu/B12 G, the number of H.E.-stained or PCNA-immunolabelled spermatogonia increased fourfold in comparison with BuG. The structural changes in ST after 6 days of busulphan exposure may be associated with the potential effect of this anti-neoplastic agent on SC. The increased number of spermatogonia in the busulphan-treated animals receiving vitamin B12 indicates that this vitamin can be an adjuvant therapy to improve the fertility in male cancer patients.
Subject(s)
Adult Germline Stem Cells/drug effects , Antineoplastic Agents, Alkylating/toxicity , Busulfan/toxicity , Seminiferous Epithelium/drug effects , Vitamin B 12/pharmacology , Adult Germline Stem Cells/pathology , Animals , Body Weight/drug effects , Leukopenia/chemically induced , Leukopenia/prevention & control , Male , Organ Size/drug effects , Rats, Sprague-Dawley , Seminiferous Epithelium/pathology , Sertoli Cells/drug effects , Sertoli Cells/pathology , Spermatogenesis/drug effects , Testis/drug effects , Testis/metabolism , Testis/pathology , Thrombocytopenia/chemically induced , Thrombocytopenia/prevention & control , Vimentin/metabolismABSTRACT
Nicotinamide adenine dinucleotide (NAD) is an essential co-factor in glycolysis and is a key molecule involved in maintaining cellular energy metabolism. Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step of an important salvage pathway in which nicotinamide is recycled into NAD. NAMPT is up-regulated in many types of cancer and NAMPT inhibitors (NAMPTi) have potential therapeutic benefit in cancer by impairing tumor metabolism. Clinical trials with NAMPTi APO-866 and GMX-1778, however, failed to reach projected efficacious exposures due to dose-limiting thrombocytopenia. We evaluated preclinical models for thrombocytopenia that could be used in candidate drug selection and risk mitigation strategies for NAMPTi-related toxicity. Rats treated with a suite of structurally diverse and potent NAMPTi at maximum tolerated doses had decreased reticulocyte and lymphocyte counts, but no thrombocytopenia. We therefore evaluated and qualified a human colony forming unit-megakaryocyte (CFU-MK) as in vitro predictive model of NAMPTi-induced MK toxicity and thrombocytopenia. We further demonstrate that the MK toxicity is on-target based on the evidence that nicotinic acid (NA), which is converted to NAD via a NAMPT-independent pathway, can mitigate NAMPTi toxicity to human CFU-MK in vitro and was also protective for the hematotoxicity in rats in vivo. Finally, assessment of CFU-MK and human platelet bioenergetics and function show that NAMPTi was toxic to MK and not platelets, which is consistent with the clinically observed time-course of thrombocytopenia.
Subject(s)
Antineoplastic Agents/adverse effects , Enzyme Inhibitors/adverse effects , Hematopoiesis/drug effects , Megakaryocytes/drug effects , Niacin/metabolism , Nicotinamide Phosphoribosyltransferase/antagonists & inhibitors , Thrombocytopenia/chemically induced , Animals , Antineoplastic Agents/chemistry , Blood Platelets/drug effects , Blood Platelets/metabolism , Cells, Cultured , Colony-Forming Units Assay , Dietary Supplements , Drug Evaluation, Preclinical , Enzyme Inhibitors/chemistry , Food-Drug Interactions , Humans , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Macaca fascicularis , Male , Megakaryocytes/cytology , Megakaryocytes/metabolism , Megakaryocytes/pathology , Mice , Molecular Structure , Niacin/therapeutic use , Nicotinamide Phosphoribosyltransferase/genetics , Nicotinamide Phosphoribosyltransferase/metabolism , Pentosyltransferases/genetics , Pentosyltransferases/metabolism , Rats, Sprague-Dawley , Thrombocytopenia/metabolism , Thrombocytopenia/prevention & controlABSTRACT
PURPOSE OF REVIEW: Low-molecular-weight heparins are in widespread use during pregnancy. As with every treatment in pregnant patients, concerns have been raised about the safety of Low-molecular-weight heparins. The purpose of the present article is to review recent advances, published during the past year, that have studied the maternal, fetal, and neonatal safety of Low-molecular-weight heparins in pregnant women. RECENT FINDINGS: Low-molecular-weight heparins do not increase the risk of maternal bleeding during pregnancy. Closed management is needed during the peripartum period, and discontinuing Low-molecular-weight heparins at least 12 h before delivery seems sufficient to prevent post-partum haemorrhage. The incidence of Low-molecular-weight heparins-induced immune reaction is low. Fondaparinux or danaparoid may be used as an alternative option in pregnant women with heparin-induced thrombocytopenia. Long-term Low-molecular-weight heparins therapy may be associated with osteopenia. Calcium vitamin D supplementation during pregnancy may reduce the risk of Low-molecular-weight heparins-induced osteoporosis. As Low-molecular-weight heparins do not cross the placenta, no fetal or neonatal complication has been reported. Beyond the safety question, Low-molecular-weight heparins have the potential to improve the live-birth rate in high-risk pregnancies (antiphospholipid syndrome, thrombophilia, or recurrent fetal loss). SUMMARY: Recent studies have confirmed the safety of Low-molecular-weight heparins therapy during pregnancy. The risk of potential side effects is low for both the mother and the neonate.
Subject(s)
Anticoagulants/adverse effects , Bone Density Conservation Agents/administration & dosage , Heparin, Low-Molecular-Weight/adverse effects , Pregnancy Complications, Hematologic/drug therapy , Thrombosis/prevention & control , Anticoagulants/therapeutic use , Bone Diseases, Metabolic/prevention & control , Calcium, Dietary/administration & dosage , Female , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Postpartum Hemorrhage/prevention & control , Pregnancy , Pregnancy Outcome , Risk Assessment , Safety , Thrombocytopenia/chemically induced , Thrombocytopenia/prevention & control , Vitamin D/administration & dosageABSTRACT
Pegylated interferon and ribavirin combination therapy represent the standard-of-care treatment for chronic hepatitis C, that allows to cure more than half of the patients. However, the success of this bitherapy is in balance with numerous side effects, especially hematologic and psychiatric. This review is focused on complementary treatments (erythropoietin, G-CSF, vitamin E, glutathion, ursodeoxycholic acid and antidepressants) likely to bring a benefit in maintaining adequate interferon and ribavirin dosages and in improving quality of life. This analysis has been performed by using the Medline(R) data base and with data from laboratories which commercialized these molecules. Erythropoietin, G-CSF and antidepressants are the best tools to optimize the bitherapy in its dose and its duration while privileging the quality of life of HCV-infected patients.
Subject(s)
Antiviral Agents/adverse effects , Hepatitis C, Chronic/drug therapy , Interferon-alpha/adverse effects , Polyethylene Glycols/adverse effects , Ribavirin/adverse effects , Anemia/chemically induced , Anemia/prevention & control , Antidepressive Agents/therapeutic use , Antioxidants/therapeutic use , Antiviral Agents/administration & dosage , Erythropoietin/therapeutic use , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Neutropenia/chemically induced , Neutropenia/prevention & control , Polyethylene Glycols/administration & dosage , Recombinant Proteins , Ribavirin/administration & dosage , Thrombocytopenia/chemically induced , Thrombocytopenia/prevention & controlABSTRACT
Heparin-induced thrombocytopenia syndrome is a serious, potentially life-threatening adverse reaction to the use of heparin anticoagulation therapy that can result in significant skin damage and organ morbidity. A case study design is used to describe the innovative use of a topical wound treatment (trypsin-balsam of Peru-castor oil ointment) on bullous lesions related to the effects of this syndrome. An elderly, morbidly obese woman was treated for 2 weeks with twice-daily applications of the product along with non-adherent oil emulsion dressings. Oozing decreased substantially within a few days and open blisters closed within 1 week. After 2 weeks of therapy, the bullous skin reaction was fully resolved with no recurrence. The results of this case study suggest that this topical product may have had a positive effect on the bullous lesions and should be considered for use in other similar significant integumentary reactions.
Subject(s)
Anticoagulants/adverse effects , Balsams/therapeutic use , Blister , Castor Oil/therapeutic use , Heparin/adverse effects , Thrombocytopenia , Trypsin/therapeutic use , Administration, Cutaneous , Aged , Balsams/chemistry , Bandages , Blister/chemically induced , Blister/prevention & control , Castor Oil/chemistry , Chemistry, Pharmaceutical , Drug Combinations , Female , Humans , Nurse Clinicians , Nursing Assessment , Obesity, Morbid/complications , Ointments , Skin Care/methods , Skin Care/nursing , Syndrome , Thrombocytopenia/chemically induced , Thrombocytopenia/prevention & control , Treatment Outcome , Trypsin/chemistry , Wound HealingABSTRACT
OBJECTIVE: To investigate the effect of Sarcandra glabra Thunb on prevention and treatment of thrombocytopenia after chemotherapy with a large dosage. METHODS: The Babl/c mice model of thrombocytopenia was made by intraperitoneal injection of 5-FU at a large dosage. All mice were poured Sarcandra glabra Thunb dilution to the mice's stomach once daily from the beginning of the experiment. Then the effect was analyzed by measuring peripheral blood cell counts of the mice on the 2nd day, the 4th day and the 7th day after chemotherapy. On the end of 7th day, all mice were killed, and then bone marrow biopsy was employed to investigate the hemapoietic condition. RESULTS: Before the chemotherapy, the platelet counts of mice treated by Sarcandra glabra Thunb were higher than that in the control group (P < 0.05). After chemotherapy with 5-FU, the platelet counts were not significantly decreased in two all experimental groups compared with negative control group (P < 0.05), while there was not significantly different between two experimental groups (P > 0.05). Moreover the marrow biopsy showed that bone marrow hyperplasia was active in two intervention study groups with some megaryocytes in the medullary cavity of bone while bone marrow hyperplasia was low in the control group without any megaryocyte in the medullary cavity of bone. CONCLUSION: The Sarcandra glabra Thunb had obvious activity in treatment to therombocytopenia and can prevent thrombocytopenia by 5-FU.
Subject(s)
Drugs, Chinese Herbal/administration & dosage , Magnoliopsida/chemistry , Plants, Medicinal/chemistry , Thrombocytopenia/prevention & control , Animals , Antineoplastic Agents/adverse effects , Erythrocyte Count , Fluorouracil/administration & dosage , Hematopoiesis/drug effects , Male , Mice , Mice, Inbred BALB C , Platelet Count , Thrombocytopenia/blood , Thrombocytopenia/chemically inducedABSTRACT
Platelets are known to play a role in blood borne metastasis. Previous experimental studies have suggested that platelet GpIIb/IIIa may be a therapeutic target. However, the need for intravenous administration limits the potential application of current GpIIb/IIIa inhibitors to cancer therapy. The aim of the present study was to assess the efficacy of a novel, non-peptide oral GpIIb/IIIa antagonist (XV454) on tumor cell-induced platelet aggregation in vivo and on experimental metastasis. A Lewis lung carcinoma (LL2) mouse model of experimental metastasis was used in this study. XV454 (100 micro g) was administered intravenously (via tail vein) or orally (gavages) to 20 g mice. To determine the effect of XV454 on platelet aggregation, blood samples were collected by cardiac puncture 10 minutes after intravenous and 1-24 hrs after oral XV454, and platelet function was assessed by aggregometry, thrombelastography and the Platelet Function Analyzer (PFA100). The effect of XV454 on tumor cell-induced thrombocytopenia was determined 10 minutes after intravenous and 3 hrs after oral XV454 administration. Tumor cells (2 x 10(6)) were injected intravenously and 15 minutes after cell injection, platelet count was measured and compared to baseline (pre-injection) counts. To assess the effect on metastasis, XV454 was administered intravenous or orally 10 minutes and 3 hrs before tumor cell injection, respectively. Eighteen days later, surface lung tumor nodules were counted and the total lung tumor burden assessed. In a fourth group, in addition to the initial oral dose (before tumor cell injection), oral XV454 was given daily for the first week and three times in the second week. Administration of XV454 (5 mg/kg) completely inhibited platelet aggregation and this effect persisted for at least 24 hrs after oral delivery. Both intravenous and oral XV454 significantly inhibited tumor cell-induced thrombocytopenia (P < 0.01), the number of surface lung tumor nodules (80-85%; P < 0.001) and total tumor burden (83% for intravenous group; 50% oral [single treatment] group; 91% oral [multiple treatment] group, P < 0.001). Overall, these data provide further evidence for the effect of oral and intravenous GpIIb/IIIa antagonism on tumor cell-platelet interaction and metastasis.
Subject(s)
Alanine/analogs & derivatives , Alanine/pharmacology , Carcinoma, Lewis Lung/blood , Lung Neoplasms/drug therapy , Neoplasm Metastasis/prevention & control , Oxazoles/pharmacology , Platelet Aggregation/drug effects , Administration, Oral , Alanine/administration & dosage , Animals , Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/pathology , Cell Line, Tumor , Drug Evaluation, Preclinical , Female , Lung Neoplasms/blood , Lung Neoplasms/secondary , Mice , Mice, Nude , Neoplasm Metastasis/drug therapy , Oxazoles/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/pharmacology , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Thrombocytopenia/etiology , Thrombocytopenia/prevention & controlABSTRACT
This study investigates the potential role of the recombinant c-mpl ligands (recombinant human thrombopoietin [rhTPO] and pegylated recombinant human megakaryocyte growth and development factor [PEG-rhMGDF]) on the recovery of platelet counts after TBI with and without allogeneic hematopoietic stem cell transplantation (HSCT) in an established canine model. Initially, 3 cohorts, each with 2 nonirradiated dogs, received increasing doses of rhTPO (5 microg/kg per day; 10 microg/kg per day; 20 microg/kg per day) for 7 days to determine the optimal dose. The dose of 10 microg/kg per day of rhTPO was selected for subsequent studies. Ten dogs then received either rhTPO or placebo for 28 days after 200 cGy TBI without HSCT. The rhTPO group had fewer days with platelet counts <20,000/microL (9.8 days versus 17.8 days, P < .05) and significantly increased granulocyte counts (n = 5) compared to the controls (n = 5). RhTPO-specific antibodies developed in 2 dogs, which caused a significant but transient decrease of the platelet counts. Retreatment of these sensitized dogs with rhTPO resulted in profound transient decreases in platelet counts. In the next study, 20 dogs received either PEG-rhMGDF or placebo for 21 days after 920 cGy TBI and allogeneic HSCT. The median time to platelet recovery (>20,000/microL) for the PEG-rhMGDF group (n = 10) was 14.0 days compared to 15.5 days for the control group (n = 10; log rank, P = .35). There were no significant differences in the total time to platelet counts <20,000/microL or in the time to recover neutrophil counts >500/microL. The effects of rhTPO on recovery of platelet and granulocyte counts after sublethal TBI were modest, and no effects of PEG-rhMGDF were observed on hematopoietic recovery after high-dose TBI and allogeneic HSCT. The significant effect that rhTPO-specific antibodies had on the platelet counts may limit the clinical role of recombinant c-mpl ligands unless sensitization can be prevented.
Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Thrombopoietin/pharmacology , Whole-Body Irradiation/adverse effects , Animals , Blood Platelets/drug effects , Blood Platelets/radiation effects , Bone Marrow Transplantation/methods , Combined Modality Therapy , Dogs , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Drug Evaluation, Preclinical , Hematopoiesis/drug effects , Hematopoiesis/radiation effects , Isoantibodies/blood , Platelet Count , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/pharmacology , Recombinant Proteins/administration & dosage , Recombinant Proteins/immunology , Recombinant Proteins/pharmacology , Thrombocytopenia/etiology , Thrombocytopenia/prevention & control , Thrombopoietin/administration & dosage , Thrombopoietin/immunology , Transplantation, Homologous/methodsABSTRACT
Radiation-induced pancytopenia proved to be a suitable model system in mice and rhesus monkeys for studying thrombopoietin (TPO) target cell range and efficacy. TPO was highly effective in rhesus monkeys exposed to the mid-lethal dose of 5 Gy (300 kV x-rays) TBI, a model in which it alleviated thrombocytopenia, promoted red cell reconstitution, accelerated reconstitution of immature CD34+ bone marrow cells, and potentiated the response to growth factors such as GM-CSF and G-CSF. In contrast to the results in the 5 Gy TBI model, TPO was ineffective following transplantation of limited numbers of autologous bone marrow or highly purified stem cells in monkeys conditioned with 8 Gy TBI. In the 5 Gy model, a single dose of TPO augmented by GM-CSF 24 h after TBI was effective in preventing thrombocytopenia. The strong erythropoietic stimulation may result in iron depletion, and TPO treatment should be accompanied by monitoring of iron status. This preclinical evaluation thus identified TPO as a potential major therapeutic agent for counteracting radiation-induced pancytopenia and demonstrated pronounced stimulatory effects on the reconstitution of immature CD34+ hemopoietic cells with multilineage potential. The latter observation explains the potentiation of the hematopoietic responses to G-CSF and GM-CSF when administered concomitantly. It also predicts the effective use of TPO to accelerate reconstitution of immature hematopoietic cells as well as possible synergistic effects in vivo with various other growth factors acting on immature stem cells and their direct lineage-committed progeny. The finding that a single dose of TPO might be sufficient for a clinically significant response emphasizes its potency and is of practical relevance. The heterogeneity of the TPO response encountered in the various models used for evaluation points to multiple mechanisms operating on the TPO response and heterogeneity of its target cells. Mechanistic mouse studies made apparent that the response of multilineage cells shortly after TBI to a single administration of TPO is quantitatively more important for optimal efficacy than the lineage-restricted response obtained at later intervals after TBI and emphasized the importance of a relatively high dose of TPO to overcome initial c-mpl-mediated clearance. Further elucidation of mechanisms determining efficacy might very well result in a further improvement, e.g., following transplantation of limited numbers of stem cells. Adverse effects of TPO administration to myelosuppressed or stem cell transplanted experimental animals were not observed.
Subject(s)
Hematopoietic Stem Cell Transplantation , Thrombocytopenia/prevention & control , Thrombopoietin/pharmacology , Animals , Disease Models, Animal , Humans , Immunity/radiation effects , Mice , Primates , Recombinant Proteins/pharmacology , Thrombocytopenia/drug therapy , Thrombocytopenia/etiologyABSTRACT
In this study we examined the ability of the furofuran lignan yangambin to influence the local and systemic responses induced by antigen or PAF in actively sensitized or normal rats. Given intraperitoneally 1 h before stimulation, yangambin inhibited the pleural neutrophil and eosinophil infiltration evoked by the i.pl. injection of PAF or antigen into normal or 14 daysensitized rats whereas plasma exudation evoked by both stimuli was unaffected. The pleural neutrophil influx (6 h) after LTB4 stimulation was also significantly inhibited by yangambin. We also evidenced that the hemoconcentration, thrombocytopenia, and leucocytosis noted after i.v. PAF were all attenuated by yangambin. In actively sensitized rats, pretreatment with yangambin failed to modify the antigen-induced hemoconcentration and leucocytosis, but dose-dependently abrogated the thrombocytopenia noted 1 h post-stimulation. In vitro, the anaphylactic contraction of longitudinal jejunal segments to antigen challenge was significantly inhibited by yangambin (10(-5)-10(-4) M). Likewise, the contraction of jejunal segments from normal rats to PAF was markedly blocked by yangambin under conditions where the response to 5-hydroxytryptamine (5-HT) was not altered. In conclusion, our results show that antigen- and PAF-induced pleural neutrophil and eosinophil accumulation, but not exudation, is sensitive to treatment with yangambin. In addition, yangambin also suppressed the pleural neutrophil infiltration triggered by LTB4 as well as the blood thrombocytopenia and intestinal anaphylaxis elicited by antigen in rats. Thus, our findings indicate that yangambin shows an antagonistic action on receptors other than those of PAF, i.e., LTB4, and strongly suggest that it may be a useful drug in the treatment of some allergic inflammatory responses.
Subject(s)
Anti-Allergic Agents , Eosinophils/physiology , Furans/pharmacology , Lignans/pharmacology , Neutrophils/physiology , Platelet Activating Factor/antagonists & inhibitors , Animals , Eosinophils/drug effects , Female , Leukocytosis/chemically induced , Leukocytosis/prevention & control , Male , Neutrophils/drug effects , Plant Extracts , Platelet Activating Factor/toxicity , Pleurisy/chemically induced , Pleurisy/immunology , Pleurisy/prevention & control , Rats , Rats, Wistar , Thrombocytopenia/chemically induced , Thrombocytopenia/prevention & controlABSTRACT
Megakaryocyte growth and development factor (MGDF) is a potent inducer of megakaryopoiesis in vitro and thrombopoiesis in vivo. The effects of MGDF appear to be lineage-selective, making this cytokine an ideal candidate for use in alleviating clinically relevant thrombocytopenias. This report describes a murine model of life-threatening thrombocytopenia that results from the combination treatment of carboplatin and sublethal irradiation. Mortality of this regimen is 94% and is associated with widespread internal bleeding. The daily administration of pegylated recombinant human MGDF (PEG-rMGDF) significantly reduced mortality (to < 15%) and ameliorated the depth and duration of thrombocytopenia. The severity of leucopenia and anemia was also reduced, although it was not clear whether these effects were direct. Platelets generated in response to PEG-rMGDF were morphologically indistinguishable from normal platelets. PEG-rMGDF administered in combination with murine granulocyte colony-stimulating factor completely prevented mortality and further reduced leukopenia and thrombocytopenia. These data support the concept that PEG-rMGDF may be useful to treat iatrogenic thrombocytopenias.
Subject(s)
Carboplatin/toxicity , Immunologic Factors/therapeutic use , Radiation Injuries, Experimental/complications , Recombinant Proteins/therapeutic use , Thrombocytopenia/prevention & control , Thrombopoietin/therapeutic use , Animals , Drug Evaluation, Preclinical , Drug Synergism , Female , Granulocyte Colony-Stimulating Factor/therapeutic use , Hemorrhage/etiology , Hemorrhage/prevention & control , Humans , Leukopenia/etiology , Leukopenia/therapy , Mice , Mice, Inbred BALB C , Platelet Count , Polyethylene Glycols , Thrombocytopenia/etiology , Thrombopoietin/chemistryABSTRACT
The immunomodulator AS101 has previously been found to induce mouse and human hematopoietic cells to secrete cytokines such as interleukin-1 alpha (IL-1 alpha), IL-2, tumor necrosis factor-alpha (TNF-alpha), and gamma interferon (IFN-gamma). The compound was shown to protect mice from lethal and sublethal effects of chemotherapy and irradiation. AS101 prevented the decrease in the number of bone marrow (BM) and spleen myeloid progenitor cells, and increased the survival of lethally treated mice. In this study, we show a dose-dependent response of AS101 in the induction of high secretion levels of IL-6, IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and stem cell factor (SCF). Since these growth factors are known to induce the proliferation and differentiation of multilineage progenitors, including megakaryocytic and erythroid progenitors, we designed this study to evaluate the role of AS101 in attenuating thrombocytopenia, anemia, and multilineage myelosuppression associated with chemotherapy. We demonstrate that pretreatment of mice with AS101 24 hours before intraperitoneal injection of 250 mg/kg cyclophosphamide (CYP) or intravenous injection of 150 mg/kg 5-fluorouracil (5-FU) significantly increased the number of circulating white blood cells (WBC) and platelets. The numbers of both neutrophils and lymphocytes were significantly increased in AS101-treated mice subjected to chemotherapy. In addition, AS101 attenuated erythropenia caused by 5-FU. It could also increase megakaryocyte and erythroid progenitor cells (CFU-MK and CFU-E) in the BM of treated mice severely affected by chemotherapy. We demonstrate that the protective effect of AS101 could be abrogated by treatment with anti-IL-1R or anti-SCF antibodies. We suggest that the endogenous production of cytokines such as IL-1, IL-6, IL-3, SCF, and GM-CSF in mice treated with AS101 offers protection to circulating blood elements and ameliorates the reconstitution of megakaryocytic and erythroid progenitors. The simultaneous protection by AS101 of multilineage cell compartments is probably due to stimulation by AS101 of a selective subpopulation of primitive stem cells resistant to chemotherapy. On the basis of these studies, phase II clinical trials with patients treated with chemotherapy in combination with AS101 have been initiated.